A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

NCT07484074 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema (DME)
Neovascular (Wet) Age-Related Macular Degeneration

Interventions

DRUG: Faricimab
DRUG: OLN324

Sponsor

Ollin Biosciences, Inc.